Stereotactic body radiation therapy (SBRT) is both safe and effective for men with low- and intermediate-risk prostate cancer, according to research presented Oct. 22 at the 2018 American Society for Radiation Oncology (ASTRO) Annual Meeting.

Women with early-stage breast cancer who receive large doses of radiation once a week for five weeks will experience the same long-term side effects as women who undergo conventional radiation therapy, according to a ten-year study presented Oct. 21 at the 2018 American Society for Radiation Oncology (ASTRO) annual meeting in San Antonio, Texas.

New Big Bore RT and Ingenia Ambition/Elition MR-RT imaging systems and Pinnacle Evolution treatment planning software support improved patient care, accelerated time to treatment and enhanced patient satisfaction.

Stereotactic body radiation therapy (SBRT) is a safe and effective treatment for patients with low- and intermediate-risk prostate cancer, according to research presented Oct. 22 at the American Society for Radiation Oncology (ASTRO) Annual Meeting in San Antonio, Texas.

Using high-dose, high-precision radiation therapy to treat renal cell carcinoma (RCR) is safe for patients with one kidney, according to findings presented Oct. 22 at the American Society for Radiation Oncology (ASTRO) annual meeting in San Antonio, Texas.

Contrary to recent data suggesting African-Americans face a higher mortality risk from prostate cancer than Caucasian men, a new study presented at the 2018 American Society for Radiation Oncology (ASTRO) Annual Meeting suggests African-American men may have higher cure rates when treated with radiation therapy than Caucasian men.

Black men with prostate cancer may have “comparatively higher” cure rates than white men when treated with radiation therapy, according to study results presented Oct. 22 at the American Society for Radiation Oncology (ASTRO) Annual Meeting in San Antonio, Texas.

Among women receiving radiation therapy to treat early-stage breast cancer, receiving larger individual doses was not associated with a significant increase in long-term side effects, according to a 10-year study presented Oct. 21 at the American Society for Radiation Oncology (ASTRO) Annual Meeting in San Antonio, Texas.